10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2020 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 8, 2021) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash flows from operating activities: | |||
| Net income | $ 3,513,200 | 2,115,800 | 2,444,400 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 235,900 | 210,300 | 148,200 |
| Non-cash compensation expense | 432,000 | 464,300 | 427,400 |
| Other non-cash items, net | (135,000) | (29,300) | 12,100 |
| Deferred taxes | 75,600 | (130,600) | (140,000) |
| Changes in assets and liabilities: | |||
| Increase in trade, Sanofi, and other accounts receivable | (1,356,100) | (523,700) | (236,400) |
| Increase in inventories | (529,400) | (335,500) | (387,900) |
| Decrease (increase) in prepaid expenses and other assets | 114,900 | (79,800) | (88,100) |
| Increase (decrease) in deferred revenue | 148,100 | 139,500 | (43,400) |
| Increase in accounts payable, accrued expenses, and other liabilities | 118,900 | 599,000 | 58,800 |
| Total adjustments | (895,100) | 314,200 | (249,300) |
| Net cash provided by operating activities | 2,618,100 | 2,430,000 | 2,195,100 |
| Cash flows from investing activities: | |||
| Purchases of marketable and other securities | (3,241,000) | (3,202,400) | (1,845,500) |
| Sales or maturities of marketable and other securities | 3,785,000 | 1,604,200 | 775,600 |
| Capital expenditures | (614,600) | (429,600) | (383,100) |
| Other | 0 | 0 | (10,000) |
| Net cash used in investing activities | (70,600) | (2,027,800) | (1,463,000) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of long-term debt, net of issuance costs | 1,981,900 | 0 | 0 |
| Proceeds from bridge loan facility | 1,500,000 | 0 | 0 |
| Repayment of bridge loan facility | (1,500,000) | 0 | 0 |
| Proceeds from issuance of Common Stock | 2,575,200 | 211,800 | 114,500 |
| Payments in connection with Common Stock tendered for employee tax obligations | (680,800) | (188,000) | (187,200) |
| Repurchases of Common Stock | (5,846,800) | (275,900) | (4,400) |
| Net cash used in financing activities | (1,970,500) | (252,100) | (77,100) |
| Net increase in cash, cash equivalents, and restricted cash | 577,000 | 150,100 | 655,000 |
| Cash, cash equivalents, and restricted cash at beginning of period | 1,630,300 | 1,480,200 | |
| Cash, cash equivalents, and restricted cash at end of period | 2,207,300 | 1,630,300 | 1,480,200 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest (net of amounts capitalized) | 23,200 | 25,000 | 22,300 |
| Cash paid for income taxes | 188,100 | 342,300 | 205,600 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |